Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 581

1.

Buprenorphine and naloxone interactions in methadone maintenance patients.

Mendelson J, Jones RT, Welm S, Brown J, Batki SL.

Biol Psychiatry. 1997 Jun 1;41(11):1095-101.

PMID:
9146820
[PubMed - indexed for MEDLINE]
2.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
[PubMed - indexed for MEDLINE]
3.

Buprenorphine and naloxone interactions in opiate-dependent volunteers.

Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ.

Clin Pharmacol Ther. 1996 Jul;60(1):105-14.

PMID:
8689806
[PubMed - indexed for MEDLINE]
4.

Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.

Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J.

Drug Alcohol Depend. 2000 Dec 22;61(1):85-94.

PMID:
11064186
[PubMed - indexed for MEDLINE]
5.

Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):232-5.

PMID:
18087797
[PubMed - indexed for MEDLINE]
6.

Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN.

Drug Alcohol Depend. 1998 Mar 1;50(1):1-8.

PMID:
9589267
[PubMed - indexed for MEDLINE]
7.

Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Rosado J, Walsh SL, Bigelow GE, Strain EC.

Drug Alcohol Depend. 2007 Oct 8;90(2-3):261-9. Epub 2007 May 22.

PMID:
17517480
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Mendelson J, Jones RT.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. Review.

PMID:
12738348
[PubMed - indexed for MEDLINE]
9.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
[PubMed - indexed for MEDLINE]
10.

Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.

Strain EC, Preston KL, Liebson IA, Bigelow GE.

J Pharmacol Exp Ther. 1992 Jun;261(3):985-93.

PMID:
1376362
[PubMed - indexed for MEDLINE]
11.

Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.

Seifert J, Metzner C, Paetzold W, Borsutzky M, Passie T, Rollnik J, Wiese B, Emrich HM, Schneider U.

Pharmacopsychiatry. 2002 Sep;35(5):159-64.

PMID:
12237786
[PubMed - indexed for MEDLINE]
12.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
[PubMed - indexed for MEDLINE]
13.

Buprenorphine in the treatment of opiate dependence.

Wesson DR, Smith DE.

J Psychoactive Drugs. 2010 Jun;42(2):161-75.

PMID:
20648912
[PubMed - indexed for MEDLINE]
14.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
[PubMed - indexed for MEDLINE]
15.

Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

J Clin Psychopharmacol. 1996 Feb;16(1):58-67.

PMID:
8834420
[PubMed - indexed for MEDLINE]
16.

Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance.

Stine SM, Kosten TR.

Am J Drug Alcohol Abuse. 1994 Nov;20(4):445-58.

PMID:
7832179
[PubMed - indexed for MEDLINE]
17.

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD.

Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x. Erratum in: Addiction. 2010 Jul;105(7):1332.

PMID:
20403021
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
[PubMed - indexed for MEDLINE]
19.

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group.

N Engl J Med. 2003 Sep 4;349(10):949-58.

PMID:
12954743
[PubMed - indexed for MEDLINE]
Free Article
20.

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Orman JS, Keating GM.

Drugs. 2009;69(5):577-607. doi: 10.2165/00003495-200969050-00006. Review.

PMID:
19368419
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk